CVS Health reported strong second-quarter 2026 results with total revenues of $106.1 billion and GAAP diluted EPS of $2.31 (Adjusted EPS $2.58). The company generated year-to-date cash flow from operations of $10.6 billion and raised its full-year 2026 guidance for GAAP diluted EPS to $6.84–$7.04, Adjusted EPS to $7.90–$8.10 and cash flow from operations to at least $11.5 billion. Management cited segment margin improvements—particularly in Health Care Benefits—and continued operational execution while noting elevated cost trends and macro uncertainty.

Financial Highlights

  • Total revenues: $106.1 billion for the three months ended June 30, 2026 (up 7.3% year‑over‑year).
  • GAAP diluted earnings per share: $2.31 for Q2 2026 (compared with $0.80 in Q2 2025).
  • Adjusted diluted EPS: $2.58 for Q2 2026 (compared with $1.81 in Q2 2025).
  • Operating income: $4,703 million for Q2 2026 (compared with $2,381 million in Q2 2025); consolidated adjusted operating income: $5,157 million for Q2 2026.
  • Year-to-date cash flow from operations: $10.6 billion; raised full-year 2026 cash flow from operations guidance to at least $11.5 billion.

Business Highlights

  • Health Care Benefits segment: total revenues $37.5 billion in Q2 2026; adjusted operating income improved to $2,426 million driven by Government business performance and absence of prior-year premium deficiency reserve; Medical Benefit Ratio improved to 87.4%.
  • Health Services segment: total revenues $51.8 billion in Q2 2026 (up 11.5% year‑over‑year) with adjusted operating income of $1,733 million; pharmacy drug mix and purchasing economics contributed to performance.
  • Pharmacy & Consumer Wellness segment: total revenues $33.8 billion in Q2 2026 with adjusted operating income of $1,475 million; prescription volume up (457.0 million prescriptions filled on a 30‑day equivalent basis) including contributions from Rite Aid asset acquisitions.
  • Product and service initiatives: launched comprehensive GLP-1 support across CVS Pharmacy and MinuteClinic (including a $29 MinuteClinic virtual visit for eligible adults) and expanded GLP-1 formulary options through CVS Caremark; participating in CMS Medicare GLP-1 Bridge program for eligible beneficiaries.
  • Technology and efficiency: deploying agentic AI in call centers and introducing Aetna Claims Assist Manager to streamline claims processing and improve payment accuracy, reducing manual complex-claim processing time by over 20%.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.